ONLINE FIRST ALERT!
Molecular #Plasticity Results in #Oncofetal #Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia
aacrjournals.org/bloodcancerd...
@aacrjournals.bsky.social
#childhoodcancer
#epigenetics
#precisiononcology
Read this recently published In Focus article— The Global State of Blood Cancers: An Ongoing Challenge, adapted from the 15th edition of the annual AACR Cancer Progress Report. buff.ly/ttfKgFy #ASH25
Very happy and proud to see this story finally published! 🎉🥳
#epigenetics #hematology #jmml #leukemia
Attending the #IMS25 Regulatory Session?
Check out this review article on how MRD received FDA approval as an early endpoint for myeloma and what this means for accelerated drug approval:
buff.ly/jCeKyZp
Paola Neri presents data from her recent Blood Cancer Discovery paper, "Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies" at #IMS25.
Read the article: buff.ly/vlQra5A
another illustrative study of "one-size-fits all" prognostic stratification in acute leukemia doesn't always work! The prognostic value of gene mutations commonly thought to impact risk in African-ancestry patients with T-ALL was limited!
aacrjournals.org/bloodcancerd...
Louis M. Staudt, M.D., Ph.D., has pioneered molecular classification of cancers, specifically lymphomas. Speaking with Blood Cancer Discovery’s Abigail Cleveland, Dr. Staudt shares his career experience on the path to scientific discovery. Read the Q&A:
In this recent Blood Cancer Discovery article by @morinryan.bsky.social, DNA methylation profiling reveals two BL epitypes with distinct molecular and clinical features, offering a new framework for understanding BL pathogenesis.
Read the study: buff.ly/PGqUMvz
AACR Journals in the news: buff.ly/1p578T3
In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
Read this collection of impactful Blood Cancer Discovery articles that highlight advanced lymphoma research by leveraging novel tools and techniques, uncovering molecular networks that drive oncogenesis and progression, and bringing innovative therapies to patients. buff.ly/q3NmZc2
Congratulations to Courtney D. DiNardo, MD, MSCE, and colleagues, recipients of the 2025 Blood Cancer Discovery Award for Outstanding Journal Article. Learn more and read the article: buff.ly/43MI9n0
Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
doi.org/10.1158/2643...
1,157 people with TP53-CHIP from BioBankJapan followed over a decade (vs 140,000 controls), TP53-CHIP associated with myeloid, lymphoid neoplasms, respiratory disease mortality. The impact is modulated by lifestyle (smoking and drinking). Stay healthy!
#clonalhematopoiesis
doi.org/10.1158/2643...
Now online @BCD_AACR: Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
#MMsm #CARTcell #microbiome #immunotherapy
aacrjournals.org/bloodcancerd...
Check out our new 'In Focus' article on overcoming B-cell acute lymphoblastic leukemia resistance by combining targeted and immune therapies in Blood Cancer Discovery! Big shoutout to Miguel and Grace for their fantastic work. t.co/bBuHxhKgCf
I am so excited to share that our new paper is out!
A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma
Out in Blood Cancer Discovery
doi.org/10.1158/2643-3230.BCD-24-0230
#mathonc #lymsm #BloodCancer
1/n
Cures in Crisis: Senators Baldwin and Welch hosted a forum featuring researchers, patients, and former NIH Director Monica Bertagnolli, MD, discussing the impact of recent NIH disruptions on scientific progress and patient care. Watch the recap: www.youtube.com/live/JofqSdW...
@baldwin.senate.gov
Happy to share our In Focus comment on targeting metabolism in T-ALL in #BloodCancerDiscovery, single-handedly written by @dasilva-diz.bsky.social! Thanks for the invitation to write on such an exciting topic @tanyabondar.bsky.social! @rutgerscancer.bsky.social aacrjournals.org/bloodcancerd...
Trees don't have p53,
yet are cancer-free.
No malignancies, despite
huge exposures to sunlight.
Can we learn from a tree
how to stay cancer-free?
And as this is a relapse, it is spreading and damaging vital organs at a much faster pace that the first occurrence. It also appears resistant to conventional treatments.
The curve going up from 2012. It does look like a steeper raise after 2020, but what is driving it up between 2012 and 2017?
GLP-1 drugs association with reduced risk of blood cancers (leukemias and lymphomas)
jamanetwork.com/journals/jam...
Not enough to cut funding. Now a list of over 20 health and life science topics that cannot be published by National Cancer Institute scientists without "oversight" (i.e. censorship).
If our "academic leaders" are wondering what a real leader looks like, look no further. Who will follow Dr. Varmus?
www.nytimes.com/2025/02/14/o...
Ring sideroblasts (Prussian blue reaction) in a bone marrow aspirate. Image source: @ash-hematology.bsky.social Image Bank
Hematologists & pathologists find these cells fascinating: ring sideroblasts.
While most commonly associated with #MDS or inherited genetic disorders like #XLSA or #MLASA, these cells can also result from ethanol or tuberculosis drugs - even hypothermia.
They have such an interesting history!/1
Congratulations to the new fellows.
